Neurogene Inc. Accrued Liabilities, Current
Neurogene Inc. (NGNE) had Accrued Liabilities, Current of $15.19 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Accrued Liabilities, Current $15.19M.
- 2026-03-31: Accrued Liabilities, Current $11.13M.
- 2025-12-31: Accrued Liabilities, Current $10.76M.
- 2025-09-30: Accrued Liabilities, Current $9.42M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $15.19M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $11.13M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $10.76M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $9.42M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $9.10M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $6.85M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $9.73M 10-K · filed 2026-03-24 |
| 2024-09-30 | $10.44M 10-Q · filed 2024-11-18 |
| 2024-06-30 | $7.14M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $6.82M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $17.50M 10-K · filed 2025-03-24 |
| 2022-12-31 | $5.32M 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |